Riskpilot← Back to searchSign inGet full accessEvox Therapeutics AB
ABIn liquidationOrg 5591943468Economic activity was not specified by tax authority · NACE 0000Est. 20190 employees
Revenue 2020
SEK 0
EBITDA margin
—
-194% vs 2019
Equity ratio
95.1%
Financial strength
Net profit 2020
SEK -208K
-197% vs 2019
| Revenue | SEK 0 | — |
| EBITDA | SEK -206K | -194% |
| Net profit | SEK -208K | -197% |
| Total assets | SEK 370K | +150% |
| Equity | SEK 352K | +340% |
| Employees | 0 | — |
Legal name
Evox Therapeutics AB
Org number
5591943468
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
8 februari 2019
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Company purpose
Bolagets verksamhetsföremål är att direkt eller indirekt bedriva verksamhet inom bioteknisk läkemedelsutveckling och annan verksamhet som är förenlig med det.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | — | — |
| EBITDA | −70 | −206 |
| Depreciation & amort. | −0 | −0 |
| EBIT | −70 | −206 |
| Net financials | — | −2 |
| Profit before tax | −70 | −208 |
| Tax | −0 | −0 |
| Net profit | −70 | −208 |
| Item | 2019 | 2020 |
|---|---|---|
| Total assets | 148 | 370 |
| Equity | 80 | 352 |
| Long-term debt | 0 | 0 |
| Short-term debt | 67 | 19 |
| Total debt | 67 | 19 |
EBITDA margin
-20600000.0%
This company
15.8%
Market median
-130379847% vs market
20192020
Equity ratio
95.1%
This company
38.2%
Market median
+149% vs market
20192020
Return on equity
-59.1%
This company
18.4%
Market median
-421% vs market
20192020
Net profit margin
-20800000.0%
This company
8.1%
Market median
-256790223% vs market
20192020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192020
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20192020
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-02-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BJ Liquidator | Liquidator | 2021 |
UM External Signatory | External Signatory | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Deputy Board Member | 2021 | |
| Former (2) | ||
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Evox Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bengt Junior Niklas Nygårds | Liquidator | 0 companies |
| Ulrika Margareta Ahlholm | External Signatory | 0 companies |
| Leif Gustav Andersson | Board of Directors | 0 companies |
| Inger Margareta Dahle | Deputy Board Member | 0 companies |
| Nils Per Olof Hedman | Deputy Board Member | 0 companies |
| Per Anders Lundin | Board of Directors | 0 companies |